With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

The live biotherapeutic elicited a 2.3% drop in weight loss in patients, which was maintained for weeks after dosing had ...

declared the shortage of semaglutide –the active ingredient in glucagon-like peptide 1 receptor agonist (GLP-1RA) Wegovy and Ozempic – officially over in the US. The move means compounders of the drug ...

The rates of depression were similar for the GLP-1RA group and sodium-glucose cotransporter-2 inhibitor (SGLT2i) group. However, compared to participants taking dipeptidyl peptidase-4 inhibitors ...

a glucagon-like peptide-1 receptor agonist (GLP-1RA). The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier ...